أخوي ممكن اتحط الخبر بالانجليزي
ياهو مادري شفيه عندي مو راضي يبطل
News Breaks
Stock Market & Financial Investment News
November 8, 2013
09:11 EDT PPHM Peregrine presents data on bavituximab combined with anti-CTLA-4 antibodies
Peregrine Pharmaceuticals announced the presentation of data showed that phosphatidylserine-targeting antibodies reactivate tumor immunity at multiple levels and that these antibodies, when combined with an anti-CTLA-4 antibody, yielded enhanced anti-tumor activity in a pre-clinical model of melanoma. Peregrine is planning to initiate a Phase III clinical trial in second-line non-small cell lung cancer with its lead PS-targeting antibody bavituximab by year-end. In the presentation, scientists examined the anti-tumor response of a PS-targeting antibody equivalent to bavituximab and anti-CTLA-4 combination therapy in a mouse melanoma model. Results showed that the group that received the combination resulted in superior tumor growth inhibition than with either antibody alone with no additional toxicity following multiple treatment doses. In addition, histopathological analysis showed the combination produced more inflammatory cell infiltration and tumor destruction than anti-CTLA-4 alone. The company said, "These encouraging data further support the potential of giving bavituximab to enhance the potential of other immunotherapies such as anti-CTLA-4 antibodies."
News For PPHM From The Last 14 Days
Check below for free stories on PPHM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
November 8, 2013
، مما يدل على أن الآن قد يكون الوقت المناسب للحصول على على (PPHM) بعد انخفاض في الآونة الأخيرة.